IOmet Pharma Demonstrates Superior in Vivo PK/PD Properties in Pre-Clinical IDO1, TDO and Dual IDO1/TDO Cancer …

EDINBURGH, Scotland–(BUSINESSWIRE)– Data to Be Presented April 22 at American Association for Cancer Research 2015 Annual Meeting IOmet Pharma, a privately-held company focused on cancer immunotherapy …